Independent prognostic value of KRAS mutation in resected colorectal cancer based on multi-gene sequencing

Table 1 Association between KRAS mutation status and clinicopathological features, n (%)

Clinicopathological feature	Total (n = 87)	KRAS mutant (n = 39)	KRAS wild-type (n = 48)	χ² value	P value
Tumor location				4.64	0.098
Left colon	21 (24.14)	7 (17.95)	14 (29.17)
Rectum	46 (52.87)	19 (48.72)	27 (56.25)
Right colon	20 (22.99)	13 (33.33)	7 (14.58)
Differentiation grade				4.52	0.034
Well/moderate	72 (82.76)	36 (92.31)	36 (75.00)
Poor	15 (17.24)	3 (7.69)	12 (25.00)
Lymphovascular invasion				2.86	0.091
Absent	51 (58.62)	19 (48.72)	32 (66.67)
Present	36 (41.38)	20 (51.28)	16 (33.33)
Perineural Invasion				17.132	< 0.001
Absent	75 (86.21)	27 (69.23)	48 (100.00)
Present	12 (13.79)	12 (30.77)	0 (0.00)
Preoperative pathology				0.06	0.811
Adenocarcinoma (non-special)	82 (94.25)	36 (92.31)	46 (95.83)
Mucinous adenocarcinoma	5 (5.75)	3 (7.69)	2 (4.17)
T stage				2.60	0.107
T1 + T2	5 (5.75)	0 (0.00)	5 (10.42)
T3 + T4	82 (94.25)	39 (100.00)	43 (89.58)
N stage				11.31	< 0.001
N0	12 (13.79)	0 (0.00)	12 (25.00)
N1 + N2	75 (86.21)	39 (100.00)	36 (75.00)
M stage				7.22	0.007
M0	71 (81.61)	27 (69.23)	44 (91.67)
M1	16 (18.39)	12 (30.77)	4 (8.33)
Tumor number				17.13	< 0.001
Solitary	75 (86.21)	27 (69.23)	48 (100.00)
Multiple (≥ 2)	12 (13.79)	12 (30.77)	0 (0.00)
Maximum tumor diameter				21.39	< 0.001
< 5 cm	32 (36.78)	4 (10.26)	28 (58.33)
≥ 5 cm	55 (63.22)	35 (89.74)	20 (41.67)
Preoperative tumor markers				16.29	< 0.001
Normal	65 (74.71)	21 (53.85)	44 (91.67)
Elevated	22 (25.29)	18 (46.15)	4 (8.33)
Microsatellite				0.03	0.872
Microsatellite stable	81 (93.10)	37 (94.87)	44 (91.67)
Microsatellite instability	6 (6.90)	2 (5.13)	4 (8.33)